December 28, 2021
Shionogi said on December 27 that it has commenced a global PIII study for its COVID-19 vaccine S-268019 in Vietnam, with the aim of enrolling roughly 50,000 subjects mainly in Southeast Asia. In Vietnam, the program is expected to cover...read more